Skip to main content

Edwards Lifesciences Corp statistics

  • EW · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$107.15+1.28%Close 13 Nov 2026 · Market value $61.47B

Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.

Valuation

Edwards Lifesciences Corp is valued at $61.47B on its latest close. Its price is 60.2 times its earnings.

Market value$61.47B
Enterprise value$57.84B
Price / earnings60.19
Price / sales9.21
Price / book5.66
EV / EBITDA35.87
EV / sales8.66
Price / free cash flow43.16
Price / free cash flow, own 5-year average68.37
EV / EBIT39.92
EV / free cash flow40.40
Free cash flow yield2.3%

Share price

Latest close$107.15
Day's change+1.3%
52-week high$107.69
52-week low$74.66
From 52-week high−0.5%
Return · 1 month+23.7%
Return · 3 months+19.3%
Return · year to date+25.7%
Return · 1 year+25.2%
Beta · 1 year against the S&P 5000.54
50-day average$90.42
200-day average$86.33
RSI 1480.3
Average volume · 20 sessions4.8M

Margins and returns

For fiscal 2025, as filed.

Gross margin78.0%
Operating margin20.8%
Net margin17.7%
Free cash flow margin22.0%
Return on equity10.6%
Return on assets7.8%
Return on invested capital13.7%
Return on invested capital, 5-year average19.7%
Return on capital employed10.8%
Stock-based compensation / revenue2.6%

Financial position

At the end of fiscal 2025.

Cash and equivalents$2.94B
Total debt$705.4M
Net debt−$3.52B
Current ratio3.72
Quick ratio3.44
Debt / equity0.07
Net debt / EBITDA−2.48
Interest coverage61.97

Growth

Revenue, latest quarter on a year+10.5%
Revenue, twelve months on a year+13.4%
EPS, latest quarter on a year+6.0%
EPS, twelve months on a year−24.2%
Revenue, 5-year compound+6.7%
Revenue, 10-year compound+9.3%
Net income, 5-year compound+5.4%
Free cash flow, 5-year compound+15.6%
EPS, 5-year compound+7.1%

Shares and dividends

For fiscal 2025, as filed.

Diluted shares586M
Shares outstanding, 5-year compound−1.5%
Net share repurchases$804.2M

Taxes

For fiscal 2025, as filed.

Income tax expense$216.9M
Effective tax rate17.0%

EW in the terminal

Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.